Copyright
©The Author(s) 2024.
World J Radiol. Jun 28, 2024; 16(6): 139-167
Published online Jun 28, 2024. doi: 10.4329/wjr.v16.i6.139
Published online Jun 28, 2024. doi: 10.4329/wjr.v16.i6.139
CT | MRI | |
Recommended equipment | Multidetector CT with minimum of 8 detector rows | 1.5 Tesla or 3 Tesla |
≤ 5 mm axial reconstructed slice thickness | Phased array multichannel torso coil | |
Dual-chamber injector with a saline flush | Current-generation high-speed gradients | |
Dual-chamber power injector | ||
Contrast injection rate | ≥ 3 mL/s of contrast, ≥ 300 mg iodine/mL | 2-3 mL/s of gadolinium chelate |
1.5 mL/kg of body weight | ||
Required images | Arterial phase (late arterial phase strongly preferred over early arterial phase) | Unenhanced T1-weighted in phase and opposed phase imaging |
Portal venous phase | T2-weighted imaging (fat suppression optional) | |
Delayed phase | All contrast agents: Multiphase T1-weighted imaging, preferably using a three dimensional sequence with ≤ 5 mm slice thickness | |
Pre-contrast imaging | ||
Arterial phase (late arterial phase strongly preferred over early arterial phase) | ||
Portal venous phase | ||
MRI with extracellular contrast agents or gadobenate dimeglumine | ||
Delayed phase (2 to 5 minutes after injection) | ||
MRI with gadoxetate disodium | ||
Transitional phase (2 to 5 minutes after injection) | ||
Hepatobiliary phase (about 20 minutes after injection) | ||
Suggested images | Pre-contrast, for initial diagnosis and patients treated with local-regional therapy | Multi-planar acquisition |
Multi-planar reformations | Subtraction imaging | |
Thinner slices with section thickness ≤ 3 mm | Diffusion-weighted imaging | |
1-3 hours hepatobiliary phase with gadobenate dimeglumine | ||
Dynamic phases | Bolus tracking or fixed timed delay is suggested | Bolus tracking or fixed timed delay is suggested |
Variants | Initial imaging | Size | Extrahepatic malignancy | Underlying chronic liver disease | Appropriate imaging |
Variant 1 | US | > 1 cm | No | No | US abdomen with IV contrast |
MRI abdomen without and with IV contrast | |||||
CT abdomen with IV contrast multiphase | |||||
Variant 2 | CT (non-contrast or single-phase) | > 1 cm | No | No | MRI abdomen without and with IV contrast |
MRI (non-contrast) | CT abdomen with IV contrast multiphase | ||||
Variant 3 | US | > 1 cm | Yes | No | MRI abdomen without and with IV contrast |
CT abdomen with IV contrast multiphase | |||||
Variant 4 | CT (non-contrast or single-phase) | > 1 cm | Yes | No | MRI abdomen without and with IV contrast |
MRI (non-contrast) | CT abdomen with IV contrast multiphase | ||||
FDG-PET/CT skull base to mid-thigh | |||||
Variant 5 | US | > 1 cm | No | Yes | US abdomen with IV contrast |
CT (non-contrast or single-phase) | MRI abdomen without and with IV contrast | ||||
MRI (non-contrast) | CT abdomen with IV contrast multiphase | ||||
Variant 6 | US | < 1 cm | Yes | No | MRI abdomen without and with IV contrast |
Variant 7 | CT (non-contrast or single-phase) | < 1 cm | Yes | No | MRI abdomen without and with IV contrast |
MRI (non-contrast) | CT abdomen with IV contrast multiphase | ||||
Variant 8 | US | < 1 cm | No | Yes | MRI abdomen without and with IV contrast |
CT (non-contrast or single-phase) | CT abdomen with IV contrast multiphase | ||||
MRI (non-contrast) |
US | CT (non-contrast) | MRI | Enhancement pattern (CT and MRI) | |
Hepatic hemangioma | Hyperechoic | Hypodense well-defined homogeneous lesion | T1: Hypointense | Arterial phase: Discontinuous, peripheral, nodular |
Well-defined homogeneous | T2: Markedly hyperintense | Enhancement | ||
lesions with acoustic enhancement | Portal venous and delayed phases: Progressive | |||
Rarely hypoechoic due to hepatic steatosis | Centripetal filling | |||
Hepatobiliary phase: Pseudo washout | ||||
Focal nodular hyperplasia | Difficult to detect (stealth lesion) | Difficult to detect (stealth lesion) | T1: Homogeneous isointense to slightly hypointense with hypointense stellate central scar | Arterial phase: Intense, homogenous enhancement |
Portal venous and delayed phases: Isointense or slightly hyperintense to the liver parenchyma | ||||
Variable echogenicity | Hypodense or isodense well-defined lesions | |||
T2: Isointense to slightly hyperintense | ||||
± Hyperintense central scar | ||||
Hepatobiliary phase: Isointense or slightly hyperintense to the liver parenchyma | ||||
± Central scar: Enhanced with extracellular gadolinium contrast agents, but not enhanced with HSCA | ||||
Hepatocellular adenoma | Heterogenous, well-defined lesions | Well-defined heterogenous lesion | T1: Variable signal intensity loss of signal | Arterial phase: Intense enhancement |
Highly variable echogenicity | ± Hyperdense if hemorrhagic | |||
± Hypodense if fatty | On opposed-phase if fatty | |||
± Calcification in areas of old hemorrhage | T2: Hyperintense | |||
Hepatic cyst | Anechoic, well-defined, homogenous lesion | Well-defined homogenous, hypodense lesion | T1: Hypointense | No enhancement with contrast agents |
T2: Hyperintense | ||||
Well-defined, homogenous lesion | ||||
Polycystic liver disease | Multiple cysts with features, resembling hepatic cysts US findings | Multiple cysts with features, resembling hepatic cysts CT findings | Multiple cysts with features, resembling hepatic cysts MRI findings | No enhancement with contrast agents |
Mucinous cystic neoplasm of liver | Solitary, well-defined, multiloculated anechoic lesion with septations | Well defined heterogenous lesion | T1: Variable signal intensity | ± Enhancement of wall/septations |
± Calcification | T2: Hyperintense | |||
± Septal/mural nodules | ||||
± Calcification | ||||
Cholangiocarcinoma | Heterogenous | Heterogenous hypodense lesion with capsular retraction and parenchymal atrophy | T1: Heterogeneous hypointense | Arterial phase: Peripheral, enhancement (targetoid appearance) |
Variable echogenicity | ||||
± Hypoechoic rim | T2: Peripherally hyperintense and centrally hypointensite | Portal venous and delayed phases: Progressive, persistent heterogeneous enhancement | ||
± Dilated intrahepatic bile ducts | ± Dilated intrahepatic bile ducts | |||
± Satellite lesions | ± Satellite lesions | |||
± Vascular encasement | ||||
Hepatocellular carcinoma | Variable echogenicity | Early HCC, isodense, ± hypodense if fatty | T1: Variable signal intensity, ± loss of signal | Arterial enhancement |
Portal venous, delayed and hepatobiliary phases: Washout | ||||
Progressed HCC, isodense or hypodense, occasionally hyperdense | On opposed-phase if fatty | |||
T2: Variable signal intensity, typically moderately hyperintense |
Gharbi | WHO-IWGE | US findings | CT findings | MRI findings |
Type 1 | CE1 | Unilocular cyst with wall | Well-defined hypoattenuating cyst | T1 hypointense |
Hydatid sand | Perceptible wall with mild delayed enhancement | Very T2 hyperintense | ||
Snowstorm sign | No internal enhancement | Perceptible wall with mild delayed enhancement | ||
No internal vascularity | No internal enhancement | |||
Type 3 | CE2 | Multilocular, multiseptated cyst | Multivesicular multiseptated cyst | Multivesicular multiseptated |
Honeycomb sign | Hypoattenuating daughter cysts | T2 hyperintense daughter cysts | ||
Daughter cysts | No septal enhancement | No septal enhancement | ||
Type 2 | CE3 | Cyst with detached membrane, water-lily sign (CE3a) | Heterogeneous | Heterogeneous |
Cyst with daughter vesicles in a solid matrix (CE3b) | High-attenuating internal content | T2 hypointense detached membranes | ||
Detached membranes | No internal enhancement | |||
No internal enhancement | ||||
Type 4 | CE4 | Cyst with heterogenous content | Solid appearance | T2 iso- to hypointense |
No daughter cysts | No daughter cysts | No daughter cysts | ||
Ball of wool sign | Avascular | Avascular | ||
Type 5 | CE5 | Thick calcified wall | Capsular and/or central calcifications | Very hypointense wall and intermediate to low internal signal intensity on T2-weighted images |
Complete calcification | No internal enhancement | |||
No internal enhancement |
WHO-IWGE classification | Surgery | Percutaneous treatment | Drug therapy | Suggested optimal treatment |
CE1 | Yes | Yes | < 5 cm | |
Albendazole | ||||
> 5 cm | ||||
PAIR + Albendazole | ||||
CE2 | Yes | Yes | Yes | Non-PAIR percutaneous treatment + Albendazole |
CE3a | Yes | Yes | < 5 cm | |
Albendazole | ||||
> 5 cm | ||||
PAIR + Albendazole | ||||
CE3b | Yes | Yes | Yes | Non-PAIR percutaneous treatment + Albendazole |
CE4 | Watch and wait | |||
CE5 | Watch and wait |
- Citation: Kahraman G, Haberal KM, Dilek ON. Imaging features and management of focal liver lesions. World J Radiol 2024; 16(6): 139-167
- URL: https://www.wjgnet.com/1949-8470/full/v16/i6/139.htm
- DOI: https://dx.doi.org/10.4329/wjr.v16.i6.139